394 related articles for article (PubMed ID: 22750939)
1. [Kidney and bone update : the 5-year history and future of CKD-MBD. Progress of phosphate binders].
Hanba Y; Masumoto A; Moribata M; Shigemathu T
Clin Calcium; 2012 Jul; 22(7):1059-71. PubMed ID: 22750939
[TBL] [Abstract][Full Text] [Related]
2. [Clinical aspect of recent progress in phosphate metabolism. Management of hyperphosphagtemia].
Skaguchi T; Shigematsu T
Clin Calcium; 2009 Jun; 19(6):844-51. PubMed ID: 19483280
[TBL] [Abstract][Full Text] [Related]
3. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
[TBL] [Abstract][Full Text] [Related]
4. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Lanthanum carbonate and new phosphate binders in patients with chronic kidney disease].
Negi S; Shigematsu T
Clin Calcium; 2010 Jul; 20(7):1096-102. PubMed ID: 20585189
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology of the phosphate binder, lanthanum carbonate.
Damment SJ
Ren Fail; 2011; 33(2):217-24. PubMed ID: 21332344
[TBL] [Abstract][Full Text] [Related]
6. Oral phosphate binders for the management of serum phosphate levels in dialysis patients.
Mohammed I; Hutchison AJ
J Ren Care; 2009 Mar; 35 Suppl 1():65-70. PubMed ID: 19222734
[TBL] [Abstract][Full Text] [Related]
7. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
Prajapati VA; Galani VJ; Shah PR
Saudi J Kidney Dis Transpl; 2014 May; 25(3):530-8. PubMed ID: 24821148
[TBL] [Abstract][Full Text] [Related]
8. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
Sprague SM
Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
[TBL] [Abstract][Full Text] [Related]
9. Hyperphosphatemia and phosphate binders: effectiveness and safety.
Kalaitzidis RG; Elisaf MS
Curr Med Res Opin; 2014 Jan; 30(1):109-12. PubMed ID: 24007207
[TBL] [Abstract][Full Text] [Related]
10. [Use of phosphate binder in predialysis patients].
Taniguchi M
Clin Calcium; 2009 Feb; 19(2):229-35. PubMed ID: 19182364
[TBL] [Abstract][Full Text] [Related]
11. [Phosphate binder up to date].
Shigematsu T; Sakaguchi T; Orita H
Clin Calcium; 2007 May; 17(5):772-8. PubMed ID: 17471009
[TBL] [Abstract][Full Text] [Related]
12. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
Itoh K; Tanaka M; Hashiguchi J; Funakoshi S; Nakano H; Kubo H; Kono T; Uchino J; Masaki K; Date T; Shigematsu T;
Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
[TBL] [Abstract][Full Text] [Related]
13. Phosphate binders in CKD: chalking out the differences.
Rees L; Shroff RC
Pediatr Nephrol; 2010 Mar; 25(3):385-94. PubMed ID: 19898877
[TBL] [Abstract][Full Text] [Related]
14. Optimal use of phosphate binders in chronic kidney disease.
Sonikian M; Papachristou E; Goumenos DS
Expert Opin Pharmacother; 2013 Dec; 14(18):2521-32. PubMed ID: 24215605
[TBL] [Abstract][Full Text] [Related]
15. [Management of hyperphosphatemia ; phosphate-binder].
Yokoyama K
Clin Calcium; 2009 Feb; 19(2):205-12. PubMed ID: 19182360
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients: effects on vascular calcification and mortality].
Koizumi M; Fukagawa M
Clin Calcium; 2010 Nov; 20(11):1700-8. PubMed ID: 21037391
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
Vegter S; Tolley K; Keith MS; Lok CE; Soroka SD; Morton AR
Clin Ther; 2012 Jul; 34(7):1531-43. PubMed ID: 22742885
[TBL] [Abstract][Full Text] [Related]
18. Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.
Pai AB; Shepler BM
Pharmacotherapy; 2009 May; 29(5):554-61. PubMed ID: 19397463
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.
Habbous S; Przech S; Acedillo R; Sarma S; Garg AX; Martin J
Nephrol Dial Transplant; 2017 Jan; 32(1):111-125. PubMed ID: 27651467
[TBL] [Abstract][Full Text] [Related]
20. The control of hyperphosphatemia in chronic kidney disease: which phosphate binder?
Ketteler M
Int J Artif Organs; 2009 Feb; 32(2):95-100. PubMed ID: 19363781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
